161 related articles for article (PubMed ID: 10505229)
1. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of aspartyl proteinase action. VII. Noncovalent complexes of HIV-1 aspartyl proteinase with substrate and substrate-like inhibitors].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Dec; 25(12):911-22. PubMed ID: 10734551
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of action of aspartic proteases. IV.Conformational characteristics of a substrate and an inhibitor of rhizopuspepsin ].
Kashparov IV; Popov ME; Popov EM
Bioorg Khim; 1999 Jun; 25(6):423-34. PubMed ID: 10505230
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of action of aspartic proteinases. V. Conformational characteristics of fragments of substrate-binding sites in rhizopuspepsin and HIV-1 proteinase].
Kashparov IV; Popov ME; Rumsh LD; Popov EM
Bioorg Khim; 1999 Aug; 25(8):597-602. PubMed ID: 10578465
[TBL] [Abstract][Full Text] [Related]
6. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
7. Inhibition and catalytic mechanism of HIV-1 aspartic protease.
Silva AM; Cachau RE; Sham HL; Erickson JW
J Mol Biol; 1996 Jan; 255(2):321-46. PubMed ID: 8551523
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
9. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
[TBL] [Abstract][Full Text] [Related]
10. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
[TBL] [Abstract][Full Text] [Related]
11. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.
Frutos S; Rodriguez-Mias RA; Madurga S; Collinet B; Reboud-Ravaux M; Ludevid D; Giralt E
Biopolymers; 2007; 88(2):164-73. PubMed ID: 17236209
[TBL] [Abstract][Full Text] [Related]
13. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
14. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
15. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
Wittayanarakul K; Hannongbua S; Feig M
J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
[TBL] [Abstract][Full Text] [Related]
16. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of action of aspartyl proteinases. VI. Nonvalent enzyme-inhibitory and enzyme-substrate complexes of the aspartyl proteinase rhizopus pepsin].
Kashparov IV; Popov ME; Rumsh LD; Popov EM
Bioorg Khim; 1999 Oct; 25(10):747-62. PubMed ID: 10645478
[TBL] [Abstract][Full Text] [Related]
18. Theoretical study on the mechanism of a ring-opening reaction of oxirane by the active-site aspartic dyad of HIV-1 protease.
Kóna J
Org Biomol Chem; 2008 Jan; 6(2):359-65. PubMed ID: 18175006
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region.
Geller M; Miller M; Swanson SM; Maizel J
Proteins; 1997 Feb; 27(2):195-203. PubMed ID: 9061783
[TBL] [Abstract][Full Text] [Related]
20. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
Lu Y; Yang CY; Wang S
J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
